Larimar Therapeutics
LRMR
48 hedge funds and large institutions have $160M invested in Larimar Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 16 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
30% more capital invested
Capital invested by funds: $124M → $160M (+$36.6M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7.12% less ownership
Funds ownership: 96.94% → 89.81% (-7.1%)
19% less funds holding
Funds holding: 59 → 48 (-11)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.86M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$544K |
| 3 |
Millennium Management
New York
|
+$491K |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$473K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$449K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.37M |
| 2 |
ACM
Altium Capital Management
New York
|
-$1.02M |
| 3 |
6CM
683 Capital Management
New York
|
-$570K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$426K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$382K |
LRMR Hedge Fund Activity: Q4 2022 in Review
48 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2022, worth a combined $160M — up 30% from $124M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of LRMR and 6 opened new positions — a net loss of 10 holders — while 10 trimmed existing stakes and 20 added.
The largest buyer was Citadel Advisors, adding an estimated $1.86M. The largest seller was CVI Holdings, cutting an estimated $1.37M.
- 48 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2022, down from 59 in Q3 2022.
- Funds reported $160M of Larimar Therapeutics stock for Q4 2022, up 30% quarter-over-quarter.
- 6 funds opened new Larimar Therapeutics positions in Q4 2022 and 16 closed out, a net change of -10 holders.
- The largest Larimar Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $1.86M added.
- The largest Larimar Therapeutics seller in Q4 2022 was CVI Holdings, an estimated $1.37M sold.
Based on aggregated 13F filings for Q4 2022.